What is Righteye?
Founded in 2012, RightEye, LLC operates at the intersection of ophthalmology, neurology, and software engineering. The company specializes in the development of sophisticated eye-tracking solutions that utilize gaming mechanics to assess brain health, reading disorders, and visual performance. Its flagship platform, RightEye EyeQ, provides healthcare providers with rapid, actionable reports, enabling a more precise approach to patient care and treatment monitoring.
The company's technological footprint extends beyond standard clinical settings, finding utility in high-stakes environments such as law enforcement, professional sports, and military training. By digitizing the capture of ocular movement, RightEye has effectively transformed subjective visual assessments into a quantifiable, cloud-accessible data stream. This shift toward objective, science-based diagnostics allows for the early detection of performance issues and neurological anomalies, cementing the company's status as a leader in the health-tech diagnostic space.
How much funding has Righteye raised?
Righteye has raised a total of $10.2M across 4 funding rounds:
Private Equity
$2.1M
Private Equity
$7.3M
Debt
$350K
Debt
$492K
Private Equity (2014): $2.1M, investors not publicly disclosed
Private Equity (2017): $7.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $492K featuring PPP
Key Investors in Righteye
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round to support the long-term growth and technological development of the company.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the long-term growth and technological development of the company.
What's next for Righteye?
Looking ahead, RightEye is poised to leverage its recent capital injection to expand its market reach and refine its diagnostic algorithms. The strategic focus will likely center on enhancing the scalability of its cloud-based platform to accommodate a broader range of institutional clients, including large-scale educational systems and specialized medical networks. As the demand for remote and objective health monitoring continues to accelerate, RightEye is well-positioned to integrate its scanning precision technology into standard wellness protocols.
Furthermore, the company's trajectory suggests a continued emphasis on research and development, particularly in the refinement of its reading disorder identification tools. By maintaining a focus on data-driven outcomes, RightEye is set to solidify its competitive advantage, potentially exploring new partnerships within the global health-tech market to further validate its methodology and expand its influence in the diagnostic software industry.
